Serum MMPs 7-9 and their inhibitors during glucocorticoid and anti-TNF-α therapy in pediatric inflammatory bowel disease

Scandinavian Journal of Gastroenterology

Volumn 47, Issue 7, 2012, Pages 785-794

  Mäkitalo, Laura ^a   Rintamäki, Hanne ^a   Tervahartiala, Taina ^b   Sorsa, Timo ^b   Kolho, Kaija Leena ^a  

^a UNIVERSITY OF HELSINKI AND HELSINKI UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

2 macroglobulin; children; IBD; matrix metalloproteinase; neutrophil elastase

Indexed keywords

ALPHA 2 MACROGLOBULIN; ANTIHISTAMINIC AGENT; ATORVASTATIN; AZATHIOPRINE; BUDESONIDE; CALGRANULIN; CIPROFLOXACIN; CYCLOSPORIN; GELATINASE B; GLUCOCORTICOID; HYDROXYCHLOROQUINE SULFATE; INFLIXIMAB; ISOTRETINOIN; LEFLUNOMIDE; LEUKOCYTE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE INHIBITOR; MESALAZINE; METRONIDAZOLE; MYELOPEROXIDASE; NEUTROPHIL COLLAGENASE; PREDNISOLONE; SALAZOSULFAPYRIDINE; STEROID; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; BLOOD ANALYSIS; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ACTIVITY; ENTERITIS; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FECES ANALYSIS; FEMALE; HUMAN; IMMUNOFLUORESCENCE; MALE; NEUTROPHIL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ALPHA-MACROGLOBULINS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BLOOD SEDIMENTATION; BUDESONIDE; C-REACTIVE PROTEIN; CHILD; CHILD, PRESCHOOL; COLITIS, ULCERATIVE; CROHN DISEASE; FECES; FEMALE; GLUCOCORTICOIDS; HUMANS; LEUKOCYTE ELASTASE; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASE 8; MATRIX METALLOPROTEINASE 9; PEROXIDASE; PREDNISOLONE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84862205870     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2012.677954     Document Type: Article

References (50)

1. Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011;140:1756-67.
2. Eastaff-Leung N, Mabarrack N, Barbour A, Cummins A, Barry S. Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease. J Clin Immunol 2010;30:80-9.
3. Curran S, Murray GI. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 2000;36:1621-30. (Pubitemid 30616366)
4. Ravi A, Garg P, Sitaraman SV. Matrix metalloproteinases in inflammatory bowel disease: boon or a bane? Inflamm Bowel Dis 2007;13:97-107. (Pubitemid 46080015)
5. Baugh MD, Perry MJ, Hollander AP, Davies DR, Cross SS, Lobo AJ, Taylor CJ, Evans GS. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology 1999;117:814-22. (Pubitemid 29468223)
6. Matsuno K, Adachi Y, Yamamoto H, Goto A, Arimura Y, Endo T, Itoh F, Imai K. The expression of matrix metalloproteinase matrilysin indicates the degree of inflammation in ulcerative colitis. J Gastroenterol 2003;38:348-54. (Pubitemid 36626270)
7. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002;115:3719-27. (Pubitemid 35203598)
8. Louis E, Ribbens C, Godon A, Franchimont D, De Groote D, Hardy N, et al. Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease. Clin Exp Immunol 2000;120:241-6. (Pubitemid 30304217)
9. Mäkitalo L, Sipponen T, Kärkkäinen P, Kolho KL, Saarialho-Kere U. Changes in matrix metalloproteinase (MMP) and tissue inhibitors of metalloproteinases (TIMP) expression profile in Crohn's disease after immunosuppressive treatment correlate with histological score and calprotectin values. Int J Colorectal Dis 2009;24:1157-67.
10. Sangfelt P, Carlson M, Thörn M, Lööf L, Raab Y. Neutrophil and eosinophil granule proteins as markers of response to local prednisolone treatment in distal ulcerative colitis and proctitis. Am J Gastroenterol 2001;96:1085-90. (Pubitemid 32327942)
11. Örem A, Deǧer O, Cimşit G, Bahadir S. Plasma polymorphonuclear leukocyte elastase levels and its relation to disease activity in psoriasis. Clin Chim Acta 1997;264:49-56. (Pubitemid 27336992)
12. Adeyemi EO, Neumann S, Chadwick VS, Hodgson HJ, Pepys MB. Circulating human leucocyte elastase in patients with inflammatory bowel disease. Gut 1985;26:1306-11. (Pubitemid 16134452)
13. Hayden DM, Forsyth C, Keshavarziana A. The role of matrix metalloproteinases in intestinal epithelial wound healing during normal and inflammatory states. J Surg Res 2011;168:315-24.
14. Sandborn WJ. Strategies for targeting tumour necrosis factor in IBD. Best Pract Res Clin Gastroenterol 2003;17:105-17.
15. Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007;132:863-73. (Pubitemid 46454266)
16. Rintamäki H, Salo HM, Vaarala O, Kolho KL. New means to monitor the effect of glucocorticoid therapy in children. World J Gastroenterol 2010;16:1104-9.
17. Kolho K-L, Raivio T, Lindahl H, Savilahti E. Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease. Scand J Gastroenterol 2006;41:720-5. (Pubitemid 43995015)
18. Rautelin H, Tervahartiala T, Lauhio A, Sorsa T, Kolho KL. Assessment of systemic matrix metalloproteinase and their regulator response in children with Helicobacter pylori gastritis. Scand J Clin Lab Invest 2010;70:492-6.
19. Tuomainen AM, Nyyssönen K, Laukkanen JA, Tervahartiala T, Tuomainen TP, Salonen JT, Sorsa T, Pussinen PJ. Serum matrix metalloproteinase-8- concentrations are associated with cardiovascular outcome in men. Arterioscler Thromb Vasc Biol 2007;27:2722-8. (Pubitemid 350158928)
20. Haapamäki J, Roine RP, Sintonen H, Kolho KL. Healthrelated quality of life in paediatric patients with inflammatory bowel disease related to disease activity. J Paediatr Child Health 2011;Epub ahead of print.
21. Kofla-Dlubacz A, Matusiewicz M, Iwanczak B. Correlation of MMP-3 and MMP-9 with Crohn's Disease activity in children. Dig Dis Sci 2011;Epub ahead of print.
22. Mäkitalo L, Kolho KL, Karikoski R, Anthoni H, Saarialho-Kere U. Expression profiles of matrix metalloproteinases and their inhibitors in colonic inflammation related to pediatric inflammatory bowel disease. Scand J Gastroenterol 2010;45:862-71.
23. Martínez-Borra J, López-Larrea C, González S, Fuentes D, Dieguez A, Deschamps EM, et al. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease. Am J Gastroenterol 2002;97:2350-6.
24. Marti HP, McNeil L, Thomas G, Davies M, Lovett DH. Molecular characterization of a low-molecular-mass matrix metalloproteinase secreted by glomerular mesangial cells as PUMP-1. Biochem J 1992;285:899-905.
25. Moinzadeh P, Krieg T, Hellmich M, Brinckmann J, Neumann E, Müller-Ladner U, et al. Elevated MMP-7 levels in patients with systemic sclerosis: Correlation with pulmonary involvement. Exp Dermatol 2011;20:770-3.
26. Musiał K, Zwolińska D. Neutrophil gelatinase-associated lipocalin (NGAL) and matrix metalloproteinases as novel stress markers in children and young adults on chronic dialysis. Cell Stress Chaperones 2011;16:163-71.
27. Martínez-Fernandez A, García-Albeniz X, Pineda E, Visa L, Gallego R, Codony-Servat J, et al. Serum matrilysin levels predict outcome in curatively resected colorectal cancer patients. Ann Surg Oncol 2009;16:1412-20.
28. Garcia-Albeniz X, Pericay C, Alonso-Espinaco V, Alonso V, Escudero P, Fernández-Martos C, et al. Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab. Tumour Biol 2011;32:417-24.
29. Wiercinska-Drapalo A, Jaroszewicz J, Flisiak R, Prokopowicz D. Plasma matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 as biomarkers of ulcerative colitis activity. World J Gastroenterol 2003;9:2843-5. (Pubitemid 38054475)
30. Kapsoritakis AN, Kapsoritaki AI, Davidi IP, Lotis VD, Manolakis AC, Mylonis PI, et al. Imbalance of tissueinhibitors of metalloproteinases (TIMP) - 1 and - 4 serum levels, in patients with inflammatory bowel disease. BMC Gastroenterol 2008;8:55.
31. Wang YD, Tan XY, Zhang K. Correlation of plasma MMP-1 and TIMP-1 levels and the colonic mucosa expressions in patients with ulcerative colitis. Mediators Inflamm 2009;2009:275072.
32. Sadowski T, Steinmeyer J. Effects of non-steroidal antiinflammatory drugs anddexamethasoneonthe activityandexpression of matrix metalloproteinase-1, matrixmetalloproteinase-3 and tissue inhibitor of metalloproteinases-1 by bovine articular chondrocytes. Osteoarthritis Cartilage 2001;9F:407-15. (Pubitemid 32734343)
33. Derer S, Waetzig GH, Seegert D, Nikolaus S, Schreiber S, Rosenstiel P. A possible link between TIMP-1 induction and response to infliximab. Gut 2009;58:888.
34. Arihiro S, Ohtani H, Hiwatashi N, Torii A, Sorsa T, Nagura H. Vascular smooth muscle cells and pericytes express MMP-1, MMP-9, TIMP-1 and type I procollagen in inflammatory bowel disease. Histopathology 2001;39:50-9. (Pubitemid 32848274)
35. Hanemaaijer R, Sorsa T, Konttinen YT, Ding Y, Sutinen M, Visser H, et al. Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells. Regulation by tumor necrosis factor-alpha and doxycycline. J Biol Chem 1997;272:31504-9. (Pubitemid 28013291)
36. Gao Q, Meijer MJ, Kubben FJ, Sier CF, Kruidenier L, van Duijn W, et al. Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases. Dig Liver Dis 2005;37:584-92. (Pubitemid 44356072)
37. Kofla-Dlubacz A, Matusiewicz M, Iwanczak B. Evaluation of metalloproteinase 3 and 9 concentration in serum of children with ulcerative colitis. J Crohn's Colitis Suppl 2009;3:14.
38. Gao Q, Meijer MJ, Schlüter UG, van Hogezand RA, van der Zon JM, van den Berg M, et al. Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and -9 in Crohn's disease. Inflamm Bowel Dis 2007;13:693-702. (Pubitemid 46909983)
39. McCarthy DA, Rampton DS, Liu YC. Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease. Clin Exp Immunol 1991;86:489-93.
40. Meijer MJ, Mieremet-Ooms MA, van der Zon AM, van Duijn W, van Hogezand RA, Sier CF, et al. Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotype. Dig Liver Dis 2007;39:733-9. (Pubitemid 47053808)
41. Becker K, Niederau C, Frieling T. Fecal excretion of alpha 2-macroglobulin: a novel marker for disease activity in patients with inflammatory bowel disease. Z Gastroenterol 1999;37:597-605. (Pubitemid 29378863)
42. Kruidenier L, Kuiper I, Van Duijn W, Mieremet-Ooms MA, van Hogezand RA, Lamers CB, Verspaget HW. Imbalanced secondary mucosal antioxidant response in inflammatory bowel disease. J Pathol 2003;201:17-27. (Pubitemid 37121199)
43. Sorsa T, Tjäderhane L, Konttinen YT, Lauhio A, Salo T, Lee HM, et al. Matrix metalloproteinases: contribution to pathogenesis, diagnosis and treatment of periodontal inflammation. Ann Med 2006;38:306-21. (Pubitemid 44385100)
44. Wagner M, Peterson CG, Ridefelt P, Sangfelt P, Carlson M. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol 2008;14:5584-9.
45. Peterson CG, Sangfelt P, Wagner M, Hansson T, Lettesjö H, Carlson M. Fecal levels of leukocyte markers reflect disease activity in patients with ulcerative colitis. Scand J Clin Lab Invest 2007;67:810-20. (Pubitemid 350158774)
46. Sugi K, Saitoh O, Matsuse R, Tabata K, Uchida K, Kojima K, et al. Antineutrophil cytoplasmic antibodies in Japanese patients with inflammatory bowel disease: prevalence and recognition of putative antigens. Am J Gastroenterol 1999;94:1304-12. (Pubitemid 29214646)
47. Morohoshi Y, Matsuoka K, Chinen H, Kamada N, Sato T, Hisamatsu T, et al. Inhibition of neutrophil elastase prevents the development of murine dextran sulfate sodium-induced colitis. J Gastroenterol 2006;41:318-24. (Pubitemid 43834374)
48. Vandivier RW, Fadok VA, Hoffmann PR, Bratton DL, Penvari C, Brown KK, et al. Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis. Clin Invest 2002;109:661-70. (Pubitemid 34204845)
49. Adeyemi EO, Chadwick VS, Hodgson HJ. The effect of some anti-inflammatory agents on elastase release from neutrophils in-vitro. J Pharm Pharmacol 1990;42:487-90. (Pubitemid 20301485)
50. Lehtinen P, Ashorn M, Iltanen S, Jauhola R, Jauhonen P, Kolho KL, Auvinen A. Incidence trends of pediatric inflammatory bowel disease in Finland, 1987-2003, a nationwide study. Inflamm Bowel Dis 2011;17:1778-83.